Improve The Yield And Quality Of Several AAV Serotypes In Suspension Cell Culture Systems

By Eric Mauro, Jonathan Havard, Laure Robert, Alengo Nyamay’antu, Carine Morel, Julie Regnery, Elisa Berera, Samantha Convers, Pauline Schorter, Quentin Bazot, Sylvain Julien, and Patrick Erbacher

Harnessing rAAVs as viral vectors for therapeutic transgene delivery still requires improvements in yields and specificity to lower vector doses, and therefore manufacturing cost, as well as to improve patient safety.

Navigate Polyplus's research focused on developing novel technologies to ensure the manufacturing of high yielding rAAV particles using transient transfection, as well as enhancing features of rAAV vectors that act on the overall size of packaged material and specificity of delivery. Polyplus's expertise in DNA plasmid design and assembly together with their scalable transfection solutions for rAAV manufacturing creates the potential to improve both productivity and specificity of gene therapy products.